This ligand-receptor binding can be significantly enhanced by association of VEGFR with the co-receptor neuropilin-1 (NRP-1) (Soker et al. 1998) This transmembrane glycoprotein is also widely expressed in tumor cells, such as lung, stomach, colon, breast, pancreatic, and glioma cancers (Chaudhary et al. 2014), suggesting its role in increased vascularity, tumor progression, aggressiveness, and meaning poor prognosis (Lu et al. 2015). Here, NRP1 is linked to neoplasm.